Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) agreed to subscribe for 210 million yuan of a structured deposit product from Shanghai Pudong Development Bank, a Sunday Hong Kong bourse filing said.
Shares of the firm were up 5% in late morning trade Monday.
The move aims to allow the Chinese pharmaceutical company put its idle funds to better use.
The product has an expected annualized return rate of 0.7%-1.9% and will fall due in 87 days.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments